“Bullish on smaller CDMO (Contract Development and Manufacturing Organisation) companies, expecting them to deliver stronger returns as new contracts and growth opportunities emerge. This segment offers more potential compared to most large-cap pharma stocks, which are considered fairly valued after the pharma index's 18% gain.”